BioVersys AG (FRA:W33) Research & Development: €17.65 Mil (TTM As of Dec. 2025)


FRA:W33 BioVersys AG FRA:W33
7 GF Score
Price €28.00
View Full Analysis

What is BioVersys AG Research & Development?

BioVersys AG FRA:W33 -0.71% 7 Research & Development is €17.65 Mil as of Dec. 2025. GuruFocus rates FRA:W33 with a GF Score™ of 7/100.

Research & Development is the aggregate amount of research and development expenses during the year. BioVersys AG's Research & Development for the six months ended in Dec. 2025 was €11.01 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €17.65 Mil.

BioVersys AG  (FRA:W33) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BioVersys AG Research & Development Related Terms

BioVersys AG Research & Development Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Research & Development Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Research & Development
13.87 17.68

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Research & Development 6.82 6.84 6.64 11.01
FRA:W33
7GF Score
BioVersys AG FRA:W33
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €17.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €17.65 Mil mean?
BioVersys AG (FRA:W33) has a Research & Development of €17.65 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Research & Development too high?
BioVersys AG's current Research & Development is €17.65 Mil. Overall, BioVersys AG has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Research & Development compare to VRTX and REGN?
BioVersys AG's Research & Development of €17.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on BioVersys AG and its competitors. BioVersys AG's current Research & Development is €17.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (FRA:W33) has a current Research & Development of €17.65 Mil. The current Research & Development is €17.65 Mil. BioVersys AG's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For BioVersys AG (FRA:W33), the current Research & Development is €17.65 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score

Get the complete analysis for FRA:W33

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.00
Price